Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation

Abstract

Protocadherins constitute the largest subgroup in the cadherin superfamily of cell adhesion molecules. Their major functions are poorly understood, although some are implicated in nervous system development. As tumor-specific promoter methylation is a marker for tumor suppressor genes (TSG), we searched for epigenetically inactivated TSGs using methylation-subtraction combined with pharmacologic demethylation, and identified the PCDH10 CpG island as a methylated sequence in nasopharyngeal carcinoma (NPC). PCDH10 is broadly expressed in all normal adult and fetal tissues including the epithelia, though at different levels. It resides at 4q28.3 – a region with hemizygous deletion detected by array-CGH in NPC cell lines; however, PCDH10 itself is not located within the deletion. In contrast, its transcriptional silencing and promoter methylation were frequently detected in multiple carcinoma cell lines in a biallelic way, including 12/12 nasopharyngeal, 13/16 esophageal, 3/4 breast, 5/5 colorectal, 3/4 cervical, 2/5 lung and 2/8 hepatocellular carcinoma cell lines, but not in any immortalized normal epithelial cell line. Aberrant methylation was further frequently detected in multiple primary carcinomas (82% in NPC, 42–51% for other carcinomas), but not normal tissues. The transcriptional silencing of PCDH10 could be reversed by pharmacologic demethylation with 5-aza-2′-deoxycytidine or genetic demethylation with double knockout of DNMT1 and DNMT3B, indicating a direct epigenetic mechanism. Ectopic expression of PCDH10 strongly suppressed tumor cell growth, migration, invasion and colony formation. Although the epigenetic and genetic disruptions of several classical cadherins as TSGs have been well documented in tumors, this is the first report that a widely expressed protocadherin can also function as a TSG that is frequently inactivated epigenetically in multiple carcinomas.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 5
Figure 3
Figure 4
Figure 6
Figure 7

Similar content being viewed by others

References

  • Angst BD, Marcozzi C, Magee AI . (2001). J Cell Sci 114: 629–641.

  • Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C et al. (1995). EMBO J 14: 6107–6115.

  • Bolz H, von BB, Ramirez A, Bryda EC, Kutsche K, Nothwang HG et al. (2001). Nat Genet 27: 108–112.

  • Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B et al. (2004). J Clin Oncol 22: 1373–1381.

  • Di PF, Holme RH, Bryda EC, Belyantseva IA, Pellegrino R, Kachar B et al. (2001). Nat Genet 27: 103–107.

  • Dunne J, Hanby AM, Poulsom R, Jones TA, Sheer D, Chin WG et al. (1995). Genomics 30: 207–223.

  • Fanto M, Clayton L, Meredith J, Hardiman K, Charroux B, Kerridge S et al. (2003). Development 130: 763–774.

  • Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Scott CE et al. (2003). Genes Chromosomes Cancer 36: 361–374.

  • Frank M, Kemler R . (2002). Curr Opin Cell Biol 14: 557–562.

  • Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF et al. (1995). Cancer Res 55: 5195–5199.

  • Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P et al. (1998). Nature 392: 402–405.

  • Gumbiner BM, Yamada KM . (1995). Curr Opin Cell Biol 7: 615–618.

  • Hirano S, Yan Q, Suzuki ST . (1999). J Neurosci 19: 995–1005.

  • Hukku B, Thraves P, Dritschilo A, Rhim JS . (1997). Cancer Genet Cytogenet 93: 125–139.

  • Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA . (2004). Oncogene 23: 2250–2263.

  • Jones PA, Baylin SB . (2002). Nat Rev Genet 3: 415–428.

  • Kaneda A, Takai D, Kaminishi M, Okochi E, Ushijima T . (2003). Ann N Y Acad Sci 983: 131–141.

  • Knudson AG . (2001). Nat Rev Cancer 1: 157–162.

  • Lee SW . (1996). Nat Med 2: 776–782.

  • Mahoney PA, Weber U, Onofrechuk P, Biessmann H, Bryant PJ, Goodman CS . (1991). Cell 67: 853–868.

  • Matthews JM, Kowalski K, Liew CK, Sharpe BK, Fox AH, Crossley M et al. (2000). Eur J Biochem 267: 1030–1038.

  • Miotto E, Sabbioni S, Veronese A, Calin GA, Gullini S, Liboni A et al. (2004). Cancer Res 64: 8156–8159.

  • Nakao S, Uemura M, Aoki E, Suzuki ST, Takeichi M, Hirano S . (2005). Brain Res Mol Brain Res 134: 294–308.

  • Okazaki N, Takahashi N, Kojima S, Masuho Y, Koga H . (2002). Carcinogenesis 23: 1139–1148.

  • Paz MF, Wei S, Cigudosa JC, Rodriguez-Perales S, Peinado MA, Huang TH et al. (2003). Hum Mol Genet 12: 2209–2219.

  • Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G . (1998). Nature 392: 190–193.

  • Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST et al. (2004). Oncogene 23: 4793–4806.

  • Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE et al. (2002). Nature 416: 552–556.

  • Risinger JI, Berchuck A, Kohler MF, Boyd J . (1994). Nat Genet 7: 98–102.

  • Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP . (2000). Nat Genet 25: 338–342.

  • Rountree MR, Bachman KE, Baylin SB . (2000). Nat Genet 25: 269–277.

  • Shapiro L, Fannon AM, Kwong PD, Thompson A, Lehmann MS, Grubel G et al. (1995). Nature 374: 327–337.

  • Siemens J, Kazmierczak P, Reynolds A, Sticker M, Littlewood-Evans A, Muller U . (2002). Proc Natl Acad Sci USA 99: 14946–14951.

  • Siemens J, Lillo C, Dumont RA, Reynolds A, Williams DS, Gillespie PG et al. (2004). Nature 428: 950–955.

  • Sollner C, Rauch GJ, Siemens J, Geisler R, Schuster SC, Muller U et al. (2004). Nature 428: 955–959.

  • Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van EM, Weijenberg MP et al. (2002). Nat Genet 31: 141–149.

  • Suzuki ST . (2000). Exp Cell Res 261: 13–18.

  • Szyf M, Pakneshan P, Rabbani SA . (2004). Cancer Lett 211: 133–143.

  • Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH et al. (2002). Hum Mol Genet 11: 2091–2102.

  • Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF . (1998). J Virol 72: 7075–7083.

  • Tao Q, Swinnen LJ, Yang J, Srivastava G, Robertson KD, Ambinder RF . (1999). Am J Pathol 155: 619–625.

  • Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M et al. (2001). Cancer Res 61: 4556–4560.

  • Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z et al. (2002). Biochim Biophys Acta 1590: 150–158.

  • Ushijima T, Morimura K, Hosoya Y, Okonogi H, Tatematsu M, Sugimura T et al. (1997). Proc Natl Acad Sci USA 94: 2284–2289.

  • Waha A, Guntner S, Huang TH, Yan PS, Arslan B, Pietsch T et al. (2005). Neoplasia 7: 193–199.

  • Wolverton T, Lalande M . (2001). Genomics 76: 66–72.

  • Wu Q, Maniatis T . (2000). Proc Natl Acad Sci USA 97: 3124–3129.

  • Yagi T, Takeichi M . (2000). Genes Dev 14: 1169–1180.

  • Ying J, Srivastava G, Gao Z, Zhang X, Murray P, Ambinder R et al. (2004). Blood 103: 743–746.

  • Ying J, Srivastava G, Hsieh W-S, Gao Z, Murray P, Liao S-K et al. (2005). Clin Cancer Res, in press.

  • Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S . (1995). Proc Natl Acad Sci USA 92: 7416–7419.

  • Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ et al. (2005). Nat Genet 37: 265–274.

Download references

Acknowledgements

We thank Drs Bert Vogelstein, Soh-ha Chan, Dolly Huang, Katai Yao, Ya Cao, Guiyuan Li, Yixin Zeng, Liang Cao, Shuen-Kuei Liao and Johng S Rhim for some cell lines and reagents, and the Kazusa DNA Research Institute for the full-length clone of PCDH10. This study was supported by a Michael Kadoorie Cancer Genetics Research Fund grant (QT), The Chinese University of Hong Kong and an A*STAR grant (Johns Hopkins Singapore).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Q Tao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ying, J., Li, H., Seng, T. et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 25, 1070–1080 (2006). https://doi.org/10.1038/sj.onc.1209154

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209154

Keywords

This article is cited by

Search

Quick links